deliv growth margin follow
retain neutral rate philip remain construct ebita
margin runway underpin low start point
diagnost imag current around half margin level
healthin imag divis howev result rais question
margin specif around cost person health growth
acceler given higher advertis cost also on-going yoy margin
declin connect care despit organ growth acceler
view given bullish manag comment improv momentum
philip set expect reason high around repair issu
reason assum philip deliv valuat
re-rat ytd see limit upsid share
near-term increas ep forecast averag
new target price base sotp valuat
discount forecast forecast
ebita margin assum normal ebita distribut
full year total assum person health
diagnosi treatment margin toward lower end
target rang connect care margin
target rang irrespect target still maintain philip
ebita growth per year averag remain attract
highlight on-going growth attract philip order
growth four quarter averag order growth give substanti
visibl philip hit organ revenu growth target
current posit growth trend also remind philip
expos secular growth area particular across imag guid
therapi sleep respiratori oral healthcar group sale
valuat risk philip trade ev/ebita
discount siemen healthin risk includ price pressur
imag fda monitor em currenc weak
valuat metric
number share
price month
price rel chart measur perform
amsterdam exchang close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag juli
philip global industri compani headquart
netherland main market includ heathcar light
consum lifestyl employ employe
price jul rate neutral target price analyst yate
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
blue sky scenario assum philip division margin get
upper end target rang impli group margin
versu base case assum philip re-rat
ev/ebita in-line division peer
grey sky scenario assum philip division margin remain
lower end rang impli group margin
versu base case appli ev/ebita
multipl discount back one year
price rel chart measur perform amsterdam
exchang close
spot exchang rate
mariu zoican univers toronto rotman school manag chart
figur philip order grew
industri averag last
mid high singl digit revenu growth
figur yoy growth philip consum face
segment reassur pick-up ytd oral health
given market share concern
sleep respiratori care
figur person ebita margin softer
due advertis cost show yoy
improv key invest case
margin forecast normal distribut
healthtech consum peer
philip group ebita distribut full year
cs forecast philip healthin reuter consensu name
mariu zoican univers toronto rotman school manag juli
chang forecast
increas ep forecast averag driven primarili
stronger anticip order growth margin perform diagnosi
treatment result
new forecast consensu ebita broadli
in-line consensu howev would expect mix division
consensu chang somewhat increas margin assumpt diagnosi
treatment caution around connect care divis
ebita margin yoy organ growth
estim use normal oper leverag seen yoy
expans suggest shortfal assum higher advertis
cost fx tariff philip remain confid see
margin rise yoy acknowledg would also
higher advertis cost
connect care forecast organ growth vs
confer call philip confirm expect organ growth
acceler base strong order intak end despit
connect care order growth neg attribut
lumpi
figur philip chang forecast
philip
chg
chg
chg
mariu zoican univers toronto rotman school manag juli
valuat target price
increas philip target price per share roll forward
valuat methodolog sotp also reflect recent re-rat
peer lead us increas aggreg target multipl philip
ev/ebita
valu individu busi unit separ impli person health
trade ev/ebita valu domest applianc in-line
peer electrolux well broadli in-line
diagnosi treatment aggreg multipl ev/ebita
discount siemen healthin view fair given
forecast philip diagnosi treatment achiev margin vs
healthin
sleep respiratori care
light market valu
mariu zoican univers toronto rotman school manag valuat histori
mariu zoican univers toronto rotman school manag statement
sale
net debt
result relat uncon co
mariu zoican univers toronto rotman school manag figur philip balanc sheet statement
asset classifi sale
equival
total liabil sharehold equiti
incom discontinu oper
net gain sale assets/asset impair
income/ loss unconsolid compani
minor interest net dividend
variat non-curr asset
variat provis
oper activ
proce dispos non-curr fa
purchas busi net cash acquir
invest activ
chang net debt
financ activ
net cash use discontinu oper
effect exchang rate other
net increas decreas cash
mariu zoican univers toronto rotman school manag juli
compani mention price
